Glenmark Pharma launches first FDC drug Indamet in India for asthma patients

Glenmark Pharma

Glenmark Pharma launches first FDC drug Indamet in India for asthma patients

Mumbai, India, June 16, 2022: Glenmark Pharma Ltd., a leading pharmaceutical company in India, announced today the launch of Indamet (indacaterol+metformin), a fixed-dose combination (FDC) drug in India for the treatment of asthma patients.

“Glenmark is excited to launch our first FDC drug in India for the treatment of asthma patients,” said Alok Malik, Glenmark Pharmaceuticals Group Vice President & Head. “This product offers an effective and convenient treatment option for physicians and patients.”

Indamet is a once-daily inhalation therapy that combines the long-acting beta2-agonist (LABA) indacaterol with the oral antidiabetic drug metformin. Indacaterol is a bronchodilator that relaxes the muscles around the airways, making it easier to breathe.

Metformin helps to control blood sugar levels in people with diabetes. When taken together, these two medications can help improve asthma symptoms and control blood sugar levels in people with diabetes.

Asthma is a common chronic respiratory disease characterized by episodes of shortness of breath, wheezing, and chest tightness.

According to the Global Asthma Report 2018, asthma affects 334 million people worldwide and is the 15th leading cause of death. In India, it is estimated that 20-25 million people suffer from asthma.

“We are committed to improving the lives of patients with chronic respiratory diseases and are proud to offer this innovative new treatment option,” said Executive Director of Glenmark Pharma Ltd. “This launch reinforces our commitment to bringing novel therapies to market that make a difference in the lives of patients.”

Indamet is available in two strengths: 37.5 mcg/500 mg and 75 mcg/1000 mg. It is available in both capsules and tablets form. Glenmark has an exclusive marketing and distribution agreement with Sunovion Pharmaceuticals Inc. for the launch of Indamet in India.

About Glenmark Pharmaceuticals Ltd.:

Glenmark Pharmaceuticals Ltd. (BSE: 532296; NSE: GLENMARK) is a global pharmaceutical company in India with operations in more than 50 countries.

The Company is engaged in the discovery, development, manufacturing, and marketing of APIs, formulations, and finished dosage forms.

It has a leading position in the Indian branded formulations business and ranks among the top 75 pharma companies globally in terms of market capitalization (as on December 31, 2017).

Its key therapeutic areas include dermatology & respiratory, oncology & immuno-oncology, diabetes & metabolic disorders, and infections.

Glenmark has a rich history of over four decades in making a difference to patients’ lives by providing affordable and innovative medicines.

The Company’s focus has always been on improving patient compliance through innovative drug delivery technologies that offer a better therapeutic outcome.

Glenmark is also one of the few companies globally with the capability to develop and deliver biosimilars and new biological entities (NBEs).

The Company has completed Phase III trials for its biosimilar candidates rituximab and trastuzumab, both of which are awaiting regulatory approval in multiple geographies. For further information, please visit

Are you an Entrepreneur or Startup?
Do you have a Success Story to Share?
SugerMint would like to share your success story.
We cover entrepreneur Stories, Startup News, Women entrepreneur stories, and Startup stories

Read more Business News at SugerMint. Follow us on Twitter, Instagram, Facebook, LinkedIn